Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA.

TechNavio’s analysts forecast the Global PVA Drugs market will grow at a CAGR of 7.1 percent over the period 2013-2018.

Covered in this Report

The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA.

TechNavio’s report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

Americas

EMEA

APAC

Key Vendors

Actavis plc

Novo Nordisk A/S

Pfizer Inc.

Shionogi & Co. Ltd.

Other Prominent Vendors

ANI Pharmaceuticals Inc.

Bionovo Inc.

EndoCeutics Inc.

QuatRx Pharmaceutical Co.

PeP-Tonic Medical AB

Teva Pharmaceutical Industries Ltd.

Therapeutics MD Inc.

Upsher-Smith Laboratories Inc.

Market Driver

Significant Unmet Need.

For a full, detailed list, view our report.

Market Challenge

Increasing Number of Patent Expirations.

For a full, detailed list, view our report.

Market Trend

Increase in Awareness of PVA.

For a full, detailed list, view our report.

Key Questions Answered in this Report

What will the market size be in 2018 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.1.1 Product Offerings

Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 PVA Drugs Market in the US

06.3.1 Market Size and Forecast

06.4 PVA Drugs Market in Europe

06.4.1 Market Size and Forecast

06.5 Five Forces Analysis

07. Competitive Analysis of Marketed Products

08. Pipeline Snapshot

09. Rate of Incidence and Prevalence

10. Market Segmentation by Types

10.1 Topical Estrogen

10.1.1 Vaginal Cream

10.1.2 Vaginal Tablet

10.1.3 Vaginal Ring

10.2 Systemic Estrogen

10.2.1 Oral Estradiol

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2013

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 Pfizer Inc.

20.1.1 Business Overview

20.1.2 Business Segmentation

20.1.3 Key Information

20.1.4 SWOT Analysis

20.2 Shionogi & Co. Ltd.

20.2.1 Business Overview

20.2.2 Key Information

20.2.3 SWOT Analysis

20.3 Novo Nordisk A/S

20.3.1 Business Overview

20.3.2 Business Segmentation

20.3.3 Key Information

20.3.4 SWOT Analysis

20.4 Actavis plc

20.4.1 Business Overview

20.4.2 Business Segmentation

20.4.3 Key Information

20.4.4 SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

Exhibit 1: Market Research Methodology
Exhibit 2: Global PVA Drugs Market 2013-2018 (US$ billion)
Exhibit 3: PVA Drugs Market in the US 2013-2018 (US$ billion)
Exhibit 4: PVA Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 5: Global PVA Drugs Market Segmentation by Route of Administration
Exhibit 6: Global PVA Drugs Market by Geographical Segmentation 2013
Exhibit 7: Business Segmentation of Pfizer Inc.
Exhibit 8: Business Segmentation of Novo Nordisk A/S
Exhibit 9: Business Segmentation of Actavis plc